Immunotherapeutic targets in non-small cell lung cancer

doi:10.1111/imm.13562

Review

. 2023 Feb;168(2):256-272.

doi: 10.1111/imm.13562. Epub 2022 Aug 25.

Immunotherapeutic targets in non-small cell lung cancer

Affiliations

¹ University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
² Liver and Digestive Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.
³ Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
⁴ Department of Biochemistry and Molecular Biology, LSUHSC School of Medicine, New Orleans, Louisiana, USA.
⁵ School of Biomedical Engineering, University of Technology Sydney, Sydney, New South Wales, Australia.
⁶ Centre for Genomics and Personalised Health, School of Biomedical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia.

PMID: 35933597
DOI: 10.1111/imm.13562

Free article

Review

Immunotherapeutic targets in non-small cell lung cancer

Habib Sadeghirad et al. Immunology. 2023 Feb.

Free article

. 2023 Feb;168(2):256-272.

doi: 10.1111/imm.13562. Epub 2022 Aug 25.

Authors

Affiliations

¹ University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
² Liver and Digestive Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.
³ Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
⁴ Department of Biochemistry and Molecular Biology, LSUHSC School of Medicine, New Orleans, Louisiana, USA.
⁵ School of Biomedical Engineering, University of Technology Sydney, Sydney, New South Wales, Australia.
⁶ Centre for Genomics and Personalised Health, School of Biomedical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia.

PMID: 35933597
DOI: 10.1111/imm.13562

Abstract

Non-small cell lung cancer (NSCLC) is one of the most common types of cancer in the world and has a 5-year survival rate of ~20%. Immunotherapies have shown promising results leading to durable responses, however, they are only effective for a subset of patients. To determine the best therapeutic approach, a thorough and in-depth profiling of the tumour microenvironment (TME) is required. The TME is a complex network of cell types that form an interconnected network, promoting tumour cell initiation, growth and dissemination. The stroma, immune cells and endothelial cells that comprise the TME generate a plethora of cytotoxic or cytoprotective signalling pathways. In this review, we discuss immunotherapeutic targets in NSCLC tumours and how the TME may influence patients' response to immunotherapy.

Keywords: NSCLC; TME; immunotherapy; non-small cell lung cancer; tumour microenvironment.

PubMed Disclaimer

Cited by

Construction of immune cell infiltration score model to assess prognostic ability of tumor immune environment in lung adenocarcinoma.
Tian J, Fu C, Peng Q, Yang J, Fan X, Zeng X, Qing W, Wu Y. Tian J, et al. Am J Transl Res. 2023 Mar 15;15(3):1730-1743. eCollection 2023. Am J Transl Res. 2023. PMID: 37056847 Free PMC article.
Identifying key transcription factors and immune infiltration in non-small-cell lung cancer using weighted correlation network and Cox regression analyses.
Zhang J, Wang Y, Yuan B, Qin H, Wang Y, Yu H, Teng X, Yang Y, Zou J, Zhang M, Huang W, Wang Y. Zhang J, et al. Front Oncol. 2023 May 1;13:1112020. doi: 10.3389/fonc.2023.1112020. eCollection 2023. Front Oncol. 2023. PMID: 37197420 Free PMC article.
Duration of Immunotherapy in Non-Small Cell Lung Cancer Survivors: A Lifelong Commitment?
Putzu C, Canova S, Paliogiannis P, Lobrano R, Sala L, Cortinovis DL, Colonese F. Putzu C, et al. Cancers (Basel). 2023 Jan 22;15(3):689. doi: 10.3390/cancers15030689. Cancers (Basel). 2023. PMID: 36765647 Free PMC article. Review.
Management succinate release through SDHA by G protein-coupled receptor 91 signal, TRAP1, and SIRT3 regulation in lung cancer cells by NAR nanoparticles.
Ragab EM, Khamis AA, Mohamed TM, El Gamal DM. Ragab EM, et al. J Genet Eng Biotechnol. 2025 Mar;23(1):100464. doi: 10.1016/j.jgeb.2025.100464. Epub 2025 Feb 11. J Genet Eng Biotechnol. 2025. PMID: 40074439 Free PMC article.
The effect of median household income on the prognosis of lung adenocarcinoma: A SEER analysis.
Wang R, Lai X, Huang B, Ning X, Zhang T. Wang R, et al. Ann Med Surg (Lond). 2024 Sep 4;86(11):6416-6421. doi: 10.1097/MS9.0000000000002488. eCollection 2024 Nov. Ann Med Surg (Lond). 2024. PMID: 39525731 Free PMC article.

See all "Cited by" articles

References

REFERENCES

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49.
1. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363-85.
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
1. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-5.
1. Pan C, Liu H, Robins E, Song W, Liu D, Li Z, et al. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. J Hematol Oncol. 2020;13(1):1-15.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49.

[2] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49.

[3] Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363-85.

[4] Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363-85.

[5] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.

[6] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.

[7] Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-5.

[8] Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-5.

[9] Pan C, Liu H, Robins E, Song W, Liu D, Li Z, et al. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. J Hematol Oncol. 2020;13(1):1-15.

[10] Pan C, Liu H, Robins E, Song W, Liu D, Li Z, et al. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. J Hematol Oncol. 2020;13(1):1-15.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Immunotherapeutic targets in non-small cell lung cancer

Affiliations

Immunotherapeutic targets in non-small cell lung cancer

Authors

Affiliations

Abstract

Similar articles

Cited by

References

REFERENCES

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Abstract

Similar articles

Cited by

References

REFERENCES

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical